FDA Approves Daily Pill Sunharbo to Reduce Repeat Stroke Risk by 26%
The Food and Drug Administration (FDA) has approved Sunharbo (asundexian), a daily pill designed to help prevent repeat strokes in certain adults. This medication, manufactured by Bayer, is intended for individuals who have recently experienced an ischemic stroke caused by a clot not originating in the heart, or a transient ischemic attack (TIA). Patients take one 50-milligram pill daily in conjunction with standard antiplatelet treatment, such as aspirin. The approval is based on a phase 3 randomized trial involving 12,327 patients across 37 countries. Over an average of 14.2 months, patients receiving asundexian alongside antiplatelet therapy showed a 26% lower relative risk of ischemic stroke compared to those on a placebo with antiplatelet therapy. While major bleeding did not significantly increase overall, some groups, such as patients over 75 and those experiencing gastrointestinal bleeding, showed higher risks. The drug works by inhibiting factor XIa, a blood protein involved in clot formation, mak...